|Major advances in the use of cell-based therapies for the treatment of human diseases are rapidly emerging. These cell-based therapies include engineered immune cells, e.g., chimeric antigen receptor T cells (CAR T cells) that can kill pathologic cells that express the targeted antigen, engineered stem and progenitor cells, e.g., tissue-specific progenitor cells for regeneration of diseased/damaged tissues, and engineered differentiated cells, e.g., islet cells for restoration of insulin secretion. In all of these therapies, the ability to activate, inhibit, kill, differentiate, or image the engineered therapeutic cell type following its transplantation into the patient can be very important.
Purdue University researchers have developed a drug delivery platform that allows specific targeting of any drug for activating, inhibiting, killing, differentiating, or imaging the engineered therapeutic cell type following its transplantation into the patient. This drug delivery platform allows selective delivery of the drug to the engineered cell while preventing its uptake by any other cell in the body. The resulting "selective passageway" into the engineered cell will enable rapid and sensitive control over the biological activities of the cell-based therapies.
-Enables sensitive and rapid control of the biology of genetically engineered cells following their transplantation into a patient.
-Permits elimination of transplanted cells when toxicity is observed, e.g., GVHD, cytokine storm, tumor lysis syndrome
-Allows induction of stem cell differentiation following successful engraftment into patient
-Permits imaging of the location, proliferation, and activation of transplanted cells
-Enables fine tuning of the activation state transplanted engineered cells
Feb 17, 2018
Feb 17, 2017
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486